Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.

Leukemia & lymphoma - 1 Aug 2009

Weitzman James, Betancur Monica, Boissel Laurent, Rabinowitz Arthur P, Klein Andreas, Klingemann Hans

Abstract excerpt

Monoclonal antibodies (mAbs) are increasingly used in treatment protocols for chronic lymphocytic leukemia (CLL). Here we determined (i) the extent of antibody-dependent cellular cytotoxicity (ADCC) of four different mAbs against primary CLL cells, (ii) whether ADCC correlates with antigen density on CLL cells, and (iii) whether allogeneic natural killer (NK) cells display superior ADCC than autologous. Effector...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody-Dependent Cell Cytotoxicity

Share to Antigens, CD20

Share to Antigens, Neoplasm

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Receptors, IgG

Share to Rituximab

Source

Identifiers

PMID: 19562616
DOI: 10.1080/10428190903026500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.PMID 19562616Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity Read ↗

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.Semantic proximity Read ↗

Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.Semantic proximity Read ↗

Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca2+ mobilization and cytotoxicity in human NK cells.Semantic proximity Read ↗

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.Semantic proximity Read ↗

Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2Semantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.Semantic proximity Read ↗

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.